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The human genetic factors that affect resistance to infectious disease are poorly understood.
Here we report a genome-wide association study in 17,000 severe malaria cases and
population controls from 11 countries, informed by sequencing of family trios and by direct
typing of candidate loci in an additional 15,000 samples. We identify five replic-
able associations with genome-wide levels of evidence including a newly implicated variant
on chromosome 6. Jointly, these variants account for around one-tenth of the heritability of
severe malaria, which we estimate as ~23% using genome-wide genotypes. We interrogate
available functional data and discover an erythroid-specific transcription start site underlying
the known association in ATP2B4, but are unable to identify a likely causal mechanism at the
chromosome 6 locus. Previously reported HLA associations do not replicate in these sam-
ples. This large dataset will provide a foundation for further research on the genetic deter-
minants of malaria resistance in diverse populations.
https://doi.org/10.1038/s41467-019-13480-z OPEN
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Genome-wide association studies (GWASs) have been verysuccessful in identifying common genetic variantsunderlying chronic non-communicable diseases, but have
proved to be more difficult for acute infectious diseases that
represent a substantial portion of the global disease burden and
are most prevalent in tropical regions. This is partly due to the
practical difficulties of establishing large sample collections and
reliable phenotypic datasets in resource-constrained settings, but
also theoretical and methodological challenges associated with the
study of pathogenic diseases in populations with high levels of
genetic diversity and population structure1–3. The Malaria
Genomic Epidemiology Network (MalariaGEN) was established
in 2005 to overcome these obstacles with standardized protocols,
common phenotypic definitions, agreed policies for equitable data
sharing and local capacity building for genetic data analysis,
enabling large collaborative studies across different countries
where malaria is endemic4.
Here we extend previous work by using data collected from 11
countries to perform a comprehensive GWAS of human resis-
tance to severe malaria (SM). We incorporate DNA from 17,056
SM cases and population controls genotyped and statistically
phased at over 1.5 million single-nucleotide polymorphisms
(SNPs) across the human genome, and impute from a modified
version of the 1000 Genomes genetic variation reference panel
enriched with 773 additional African genome sequences, plus
locus-specific panels in the glycophorin and human leukocyte
antigen (HLA) regions. We analyse association in a Bayesian
meta-analysis framework, allowing for differences between
populations and subphenotypes, and identify five loci with
genome-wide levels of evidence which are further supported in a
set of replication samples and jointly explain ~10% of the esti-
mated heritability. Among these, a newly implicated locus on
chromosome 6 appears most strongly associated with cerebral
malaria (CM), but lies over 700 kb from the nearest protein-
coding gene. We analyse available functional data, including
RNA-sequencing (RNA-seq) from erythroid lineage cells, but are
unable to identify a putative function for this locus. However, this
analysis does provide insights into the potential mechanism of
protection at the previously reported ATP2B4 locus, via disrup-
tion of GATA1-mediated expression of an erythroid-specific
transcript. Across all loci, empirical models of allele frequencies
suggest there has been a systematic positive selection of malaria-
protective alleles and we conclude by noting that coevolutionary
selection pressure may also affect Plasmodium falciparum popu-
lations, raising the need to incorporate parasite genetic variation
into future studies.
Results
Human genomes reflect diversity in malaria-endemic regions.
We generated genome-wide SNP typing on samples from our
previously described case–control study, which includes records
for over 16,000 individuals admitted to a hospital with severe
symptoms of P. falciparum malaria, and 22,000 population con-
trols5. In brief, individuals were sampled from 12 study sites,
including 10 in sub-Saharan Africa and the others in Vietnam
and Papua New Guinea (PNG; Supplementary Table 1). SM was
ascertained according to the World Health Organization (WHO)
criteria6 and represents a heterogeneous phenotype including
diagnoses of CM, SM anaemia (SMA) and other malaria-related
symptoms (here referred to as other SM). For our GWAS dis-
covery phase, a subset of samples, preferentially chosen for
phenotype severity and DNA quality, were genotyped on the
Illumina Omni 2.5 M platform. We jointly processed these sam-
ples to produce a single set of estimated haplotypes for 17,960
individuals at the set of over 1.5 M SNPs genome-wide which
passed our quality control process (Methods). Subsets of these
data from The Gambia, Malawi and Kenya7, from Tanzania8 and
from selected control samples9 have been reported previously
(Supplementary Table 2). In total, this dataset includes 6888
individuals from Mali, Burkina Faso, Ghana, Nigeria, Cameroon,
Tanzania, Vietnam and PNG, which have not previously been
included in meta-analysis, and reflects the haplotype diversity of a
substantial portion of the malaria-endemic world.
Improved genotype imputation through population sequen-
cing. The ethnically diverse nature of our study provides chal-
lenges for genomic inference, including for our ability to impute
genotypes at potentially relevant untyped loci10. To address this,
we sequenced the genomes of 773 individuals from ten ethnic
groups in east and west Africa (specifically from the Gambia,
Burkina Faso, Cameroon and Tanzania), including 207 family
trios (Fig. 1). We combined genotypes at SNPs in these data with
Phase 3 of the 1000 Genomes Project to form an imputation
reference panel, which covers the most common genetic varia-
tion11 and in which two-fifths of the donor families are of African
ancestry (1203 of 3046 individuals). In principle, the additional
representation of African DNA in this panel should lead to
improvements in imputation accuracy for African study popu-
lations and we found that this was indeed the case, with the use of
our panel leading to a large increase in accuracy relative to panels
used in our previous GWAS7,10,12 and a more modest improve-
ment relative to using the 1000 Genomes Phase 3 panel alone
(Supplementary Fig. 1). Imputation of Vietnamese individuals
and those from PNG, which is substantially diverged from any
reference panel population (Fig. 1d), were less affected by the
inclusion of these additional haplotypes.
We specifically examined imputation of malaria-protective
alleles in the HBB gene, which have previously been found
difficult to impute10,12. The SNP encoding the sickle cell mutation
(rs334, chr11:5248232) was imputed with r > 0.9 in all African
populations, as compared with genotypes obtained through direct
typing5. We did note that some potentially relevant loci still
appear not to be accessible through these data, including the
common deletion of HBA1-HBA2 that causes alpha-thalassaemia
(Supplementary Note 1) and the region around the gene encoding
the invasion receptor basigin13 (Supplementary Note 2). Thus,
although overall accuracy is high across the genome, additional
work will be needed to access a smaller set of complex but
potentially relevant regions.
Association testing implicates a new locus on chromosome 6.
We used the imputed genotypes to test for association with SM
and with SM subtypes, at over 15 million SNPs and indels gen-
ome-wide, using a subset of 17,056 SM cases and controls iden-
tified without close relationships (Methods). Specifically,
association tests were conducted within each population using
logistic and multinomial logistic regression (implemented in
SNPTEST; Methods), including principal components (PCs) to
control for population structure, and we computed a fixed-effect
meta-analysis summary of association across populations (Sup-
plementary Fig. 3). In view of the complexities observed at known
association signals10,12,14, we also extended our previously
described meta-analysis method5,7 to the larger set of popula-
tions, phenotypes and variants considered here. This analysis
produces an overall measure of evidence (the model-averaged
Bayes factor, BFavg; Fig. 2a) that is sensitive to more complex
patterns of genetic effect than are detected by frequentist fixed-
effect analysis (Fig. 2b). The BFavg is computed under specific
prior weights that are detailed in Methods. In particular, BFavg
captures effects that have non-additive mode of inheritance, as
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well as effects that are restricted to particular subphenotypes or
that vary between populations.
Several regions of the genome showed evidence for association
in this analysis, including 7 regions with BFavg > 1 × 105, 12 with
BFavg > 1 × 104 (Fig. 2c), and 97 with BFavg > 1000 (Supplemen-
tary Data 1). Among these, our data convincingly replicate
previously confirmed associations at HBB, ABO, ATP2B4, and in
the glycophorin region on chromosome 4, while an additional
previously reported variant in ARL14 also shows stronger
evidence in this larger sample7. Both a direct interpretation of
the Bayes factor as well as false discovery rate (FDR) methods
suggest a relatively small number of our top signals may represent
real associations (e.g., roughly 5–9 associations among the top 97
given plausible prior odds15 of 10−6 to 10−5; 5 regions meeting
FDR < 5% based on the multinomial test Padd). Compatible with
this, direct genotyping of 15,548 cases and controls not included
in our GWAS discovery phase revealed evidence of replication
(determined as BFreplication > 1; Methods) for one newly identified
locus (rs62418762; BFreplication= 9.8; replication Padditive= 0.01
for an additive protective effect of the ‘C’ allele on CM and SMA;
Fig. 3b and Supplementary Fig. 5) from among 20 that we
attempted to replicate, in addition to previously reported regions
(Supplementary Data 1).
rs62418762 has the second strongest evidence of all SNPs in
our discovery phase and the strongest evidence overall (BFavg=
5.0 × 105; multinomial test Padd= 2.8 × 10−9; combined BF=
4.9 × 106; combined Padd= 1.7 × 10−10; Fig. 2c and Fig. 3) outside
regions of previously confirmed associations. Our estimates
suggest the rs62418762 ‘C’ allele is associated with decreased
risk of CM (ORCM= 0.79, 95% confidence interval (CI)=
0.66–0.95; estimated using only replication samples; Fig. 3b), but
less strongly with other malaria subtypes (ORSMA= 0.93, 95% CI
= 0.77–1.13; OROTHER= 1.10, 95% CI= 0.96–1.25). rs62418762
lies in a region of chromosome 6 between MAP3K7 and the
nearest gene EPHA7, which encodes Ephrin type-A receptor 7, a
regulator of neurodevelopment and neural cell adhesion16. Other
type-A ephrin receptors have been implicated in liver-stage
malaria17. However, rs62418762 lies over 700 kb distant from
EPHA7 and it is not immediately clear whether any functional
link between them exists. A number of non-protein-coding
transcripts lie nearby (e.g., the pseudogene ATF1P1), as do
reported signals of association with neurodegenerative
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Fig. 1 Overview of datasets and imputation performance. a Counts of whole-genome sequenced samples (reference panel samples, left table), samples
typed on the Omni 2.5M platform (study samples, right table) and geographic locations of sampling (map). Counts reflect numbers of samples following
our quality control process. Sequenced samples were collected in family trios, except in Burkina Faso, as shown. Colours shown in tables and map denote
country of origin of reference panel (circles) and study samples (squares), with small grey circles indicating 1000 Genomes Project populations.
b Imputation performance, measured as the mean squared correlation between directly typed and re-imputed variants for each sample. c Distribution of
the most similar haplotypes. For each GWAS sample, the average number of 1 Mb chunks such that the most similar haplotype lies in the given reference
panel population (y axis) is shown. Values are averaged over samples within each GWAS population (x axis). d, e Principal components (PCs) computed
across 17,120 study samples identified without close relationships, or the subset of 15,152 samples of African ancestry.
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disorders18,19, and these may provide clues as to an underlying
mechanism. However, we caution that no functional effect of
rs62418762 is apparent at present and additional replication may
therefore be warranted.
Malaria-associated loci show substantial heterogeneity. We
examined the nature of association at replicated loci in more
detail (Figs. 2 and 4) and observed considerable heterogeneity in
mode of effect and across populations and subphenotypes. The
sickle haemoglobin allele (HbS, encoded by rs334) is present in all
African populations studied, but varies considerably in estimated
effects, with greater than fourfold difference between the stron-
gest estimate (OR= 0.10 in the Gambia) and the weakest (OR=
0.47 in Cameroon). This does not seem to be explained by the
presence of the competing HbC mutation in West African
populations (Fig. 4), which is at low frequency in Cameroon. The
O blood group-encoding mutation rs8176719 is common in all
populations but, in our analysis, appears to have the greatest
protective effect in Africa, with an opposite direction of effect
observed in PNG, an unexpected feature that is also observed in
replication samples (rs8176719, Supplementary Fig. 5), and could
point to hitherto unexplained subtleties in the mechanism of
protection of this allele20,21. The structural variant DUP4, which
encodes the Dantu NE blood group phenotype14 and is in linkage
disequilibrium (LD) with rs567544458 in our genome-wide
imputation (Fig. 2c), is essentially absent from study popula-
tions outside east Africa (f < 0.1%, except in Malawi, Tanzania
and Kenya). Our data also demonstrate differences in effect size
between malaria subphenotypes, with all of the replicating var-
iants displaying smaller effects in nonspecific cases of SM com-
pared with cerebral or severely anaemic cases (Figs. 2d and 4a).
This likely reflects the mixed phenotypic composition of this set
of samples and contributes to the trend where replication effect
sizes are smaller than those in discovery (Supplementary Figs. 5
and 6). Inclusion of the associated variants in a joint model
suggests they act largely independently in determining malaria
risk (Fig. 4c).
A longer list of regions showing evidence for heterogeneous
effects between populations can be found in Supplementary
Data 2. We note that assessing population variation in
subphenotype-specific effects is challenging due to the relatively
small sample sizes involved, as exemplified by the wide
confidence intervals on per-population estimates for
rs62418762 (Supplementary Fig. 5), which accordingly does not
display strong evidence for between-population heterogeneity in
our data (Methods). To avoid possible effects of overfitting at
SNPs across the genome, we did not include models of between-
population heterogeneity for subphenotypes in our computation
of BFavg.
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Fig. 2 Evidence for association with severe malaria. a Association evidence (log10 BFavg, y axis; clamped to a maximum of 12) at typed and imputed SNPs
and indels genome-wide (x axis). BFavg reflects evidence under a range of models summarized using prior weights specified in Methods. Shapes denote
whether the model with the highest posterior weight is for effects fixed across populations and subphenotypes (case–control effect, circles), or suggests
variation in effect between populations (crosses) or between subphenotypes (plusses). b Comparison of model-averaged Bayes factor (log10 BFavg, y axis)
and the evidence under an additive model of association with overall SM (−log10 Padd, x axis). For visualization purposes, we have removed variants in the
region of rs334 (HbS, chromosome 11) and rs567544458 (glycophorin region, chromosome 4) except the lead variant. Shapes are as in a. The values for
rs334 and rs8176719 lie outside the plot as indicated by arrows; to visualize these we have projected them onto the plot boundary. c Twelve regions of the
genome with BFavg > 10,000. Columns reflect the ID, genomic position, reference, and alternative allele with estimated protective allele indicated in bold,
log10 BFavg, −log10 P-value for an additive model of association with SM or with SM subtypes, nearest gene and distance to the nearest gene for intergenic
variants, known linked phenotypes and combined protective allele frequency across African control and case samples. Bar plots summarize our inference
about the mode of effect of the protective allele and the distribution of effects between SM subtypes and between populations. The last column reflects the
evidence for association observed in replication samples (log10 BFreplication), assessed using the effect-size distribution learnt from discovery samples,
based on direct typing of tag SNPs as detailed in Supplementary Data 1. Rows are in bold if they showed positive replication evidence (BFreplication > 1).
d Comparison of estimated effect sizes for the protective allele on CM (y axis) and on unspecified SM cases (x axis) for the 12 variants in c. The 95%
confidence region for rs334 and rs62418762 (dashed ellipses) are shown. Source data are provided as a Source Data file.
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Fig. 4 A joint model for natural genetic resistance to malaria. a Effect sizes for severe malaria subtypes are estimated in a joint model, which includes the
five replicating associated variants and two additional variants (rs33930165, which encodes haemoglobin C, and rs8176746, which reflects the A/B blood
group) in associated regions. The model was fit across all 11 populations, assuming the effect on each phenotype is fixed across populations, and including a
population indicator and five principal components in each population as covariates. Each variant is encoded according to the mode of inheritance of the
protective allele inferred from discovery analysis. Red lines indicate the overall effect across severe malaria subtypes, computed as an inverse variance-
weighted mean of the per-phenotype estimates. Only cases with positive measured falciparum parasitaemia were included in model fit. b The frequency of
the protective allele (for effects inferred as additive) or protective genotype (for non-additive effects) of each variant in each population. Grey circles depict
the minimum, mean and maximum observed frequencies across populations. Coloured circles reflect the per-population frequencies. Frequency estimates
are computed using control samples only. c Comparison of effect-size estimates against severe malaria for combinations of genotypes (stacked circles)
carried by at least 25 study individuals, across the top six variants in a. Black filled and open circles denote the protective and risk dosage at the
corresponding variant, respectively; grey circles denote heterozygote genotype for variants with inferred additive effect. Effect-size estimates are computed
using the model as in a assuming independent effects (x axis), or jointly allowing each genotype its own effect (y axis). Source data are provided as a
Source Data file.
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Malaria risk is influenced by a polygenic component. We used
published methods to estimate the heritability of SM captured by
genome-wide genotypes (e.g., heritability explained by SNPs on
the genotyping array (h2)= 0.23, 95% CI= 0.16–0.30; computed
across African populations using PCGC22 assuming a 1% popu-
lation prevalence of SM23; Supplementary Fig. 4 and Supple-
mentary Data 3). The HBB, ABO, glycophorin and ATP2B4 loci
appear to contribute around 11% of this total (i.e., around 2.5% of
liability scale phenotype variation) and we noted a trend for the
remaining heritability to concentrate near protein-coding genes
and at lower-frequency variants (Supplementary Fig. 4d). A
number of caveats apply to these estimates, which assume a
particular relationship between effect size, allele frequency and
the degree of LD surrounding causal variants, all of which may be
distorted by effects of natural selection24,25, and may further be
affected by unmeasured environmental confounders. Never-
theless, our results are comparable to previously reported esti-
mates from family-based studies in east Africa26 and suggest that
further susceptibility loci will be discoverable with additional
data. To assist researchers to integrate our data with other sources
of information, including future genetic association studies and
functional experiments, the raw and imputed data as well as a full
set of results from our analysis are being made available (see Data
availability).
An erythroid-specific transcript underlies ATP2B4 protection.
We reasoned that functional annotations might provide clues to
further putatively causal variants among our list of most asso-
ciated regions. To assess this, we annotated all imputed variants
with information indicative of functional importance, including
location and predicted function within genes27, chromatin
state28–30 and transcriptional activity29,31,32 across cell types,
status as an expression quantitative trait loci (eQTL)32–34 and
association evidence from other traits35–38. This analysis revealed
a number of potentially functional variants with evidence of
association (Supplementary Data 4).
We uncovered compelling evidence that the association in
ATP2B4, which encodes the plasma membrane calcium pump
PMCA4, is driven by an alternative transcription start site (TSS)
that is specific to erythroid cells (Fig. 5). Specifically, we found
that associated SNPs overlap a binding site for the GATA1
transcription factor, an important regulator of expression in
erythroid cells28,30,39, in the first intron of ATP2B4. The derived
allele at one of these SNPs (rs10751451) disrupts a GATA motif32
and the same SNPs have previously been shown to associate with
ATP2B4 expression levels in whole blood34, in experimentally
differentiated erythrocyte precursors32 and with PMCA4 levels in
circulating red blood cells (RBCs)40. We noted that the
GATA1 site lies just upstream of an exon that is not listed in
the GENCODE41, RefSeq42 or ENSEMBL43 transcript models,
but that can be found in FANTOM544 (Fig. 5b). Inspection of
RNA-seq data revealed that this forms the first exon of the main
ATP2B4 transcript expressed by erythroid cells30,32,45, as well as
by the K562 cell line, but appears not to be expressed in other cell
types28,29,33 (Fig. 5a). Moreover, the derived allele, which is
associated with malaria protection, is correlated with decreased
expression of this alternative first exon (P= 0.01, using data from
24 fetal and adult erythroblasts32; Fig. 5g) and all subsequent
exons (P < 0.03) of ATP2B4, but not with the annotated first exon
(P= 0.25). These results indicate that the malaria-associated
SNPs affect ATP2B4 expression in a erythroid-specific manner, by
affecting the promoter of a TSS that is only active in these cells.
The situation outlined above for ATP2B4 is reminiscent of the
well-known mutation at the Duffy blood group locus (DARC/
ACKR1), which protects against Plasmodium vivax malaria by
preventing erythrocytic expression of the Duffy antigen receptor
through disruption of a GATA1-binding site46,47. However, the
mechanism by which ATP2B4 affects parasite processes remains
unknown. The malaria-protective allele at rs10751451 is known
to associate with RBC indices (notably with increased mean
corpuscular haemoglobin concentration (MCHC)32,36,48. We
found some evidence that genetic predisposition to high MCHC
levels may itself be associated with decreased malaria suscept-
ibility (negative observed correlation between MCHC and SM
effect size at sentinel SNPs previously identified as associated with
haematological indices in European individuals36, ρ=− 0.14,
P= 0.01; in a Mendelian randomization (MR) framework;
Fig. 5h). However, the protective effect at ATP2B4 appears
substantially stronger than this trend and suggests a genuinely
pleiotropic effect whose mechanism against malaria is yet to be
determined.
Our analysis of functional annotations revealed a number of
additional variants with some evidence of function. These include
variants in the HLA region, discussed further below, and a variant
upstream of VAC14, which has been implicated in Typhoid
fever49 and Salmonella typhi invasion35 detailed further in
Supplementary Note 4.
Classical HLA alleles appear unassociated with malaria risk.
Motivated by the modest evidence for association observed in the
HLA (Supplementary Data 1), we used a published method50 to
impute classical HLA alleles and tested for association with each
allele as described above for genome-wide variants (Fig. 6a). The
strongest evidence for association with an HLA antigen was
observed at HLA-B*42 (BFavg= 834; synonymous with HLA-
B*42:01 in this panel). By contrast, an order of magnitude
stronger evidence was observed at regional SNPs, including
rs2523650 (BFavg= 1.9 × 104; recessive model OR= 0.85 for the
non-reference ‘C’ allele; 95% CI= 0.79–0.90; Padd= 4.7 × 10−7;
Supplementary Fig. 6), which has previously been associated with
blood cell traits and expression of regional genes (Supplementary
Data 4), but this signal did not replicate in additional samples
(BFreplication= 0.19). Most notably, the HLA-B*53 allele, which
has previously been reported as associated with strong protection
against SM in the Gambia51, showed no evidence for association
across populations (BFavg= 0.17; OR= 1.0, 95% CI= 0.91–1.08
in a fixed-effect meta-analysis under a dominance model where
the effect is due to the presence of the antigen) or in any indi-
vidual population (e.g., OR= 1.02, 95% CI= 0.89–1.18 in the
Gambia, Supplementary Fig. 7).
We considered whether imperfect imputation could explain the
lack of observed association with HLA alleles. Imputed HLA
antigen frequencies were broadly consistent with published
frequencies estimated by serotyping in the same populations
(Fig. 6b) and HLA-B*53 was imputed at a reasonably high
frequency and high confidence (estimated frequency= 7–18%,
IMPUTE info score > 0.94 in all African populations). To directly
test imputation accuracy, we obtained HLA types of a subset of 31
Gambian case individuals by Sanger sequencing (Supplementary
Data 5) and confirmed that HLA-B*53 was relatively well
imputed in these samples (e.g., correlation= 0.92 between
imputed dosage and true number of copies of the allele, reflecting
five individuals imputed with probability >0.75 as heterozygote
carriers of B*53, of which one appears incorrect). However, the
closely related B*35 allele was much less accurately imputed, with
four of eight carriers imputed as having non-B*35 genotypes,
including one imputed to carry B*53. This may be the reason for
the relatively low observed frequency of imputed B*35 alleles
(Fig. 6b) and is notable because B*53 is thought to have arisen
from B*35 via a gene conversion52. Thus, although our failure to
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replicate this widely cited association appears robust, future work
to improve HLA inference in these populations is needed to
provide additional clarity.
Allele frequencies suggest polygenic positive selection. Malaria
is regarded as having played a strong role in shaping the human
genome through natural selection53,54 and observations of allele
frequency differences are commonly used to motivate the study of
specific mutations (e.g., see refs. 55–57). We sought to assess
whether variants associated with malaria susceptibility show
evidence of selection by comparing with genome-wide allele
frequency variation between populations (Fig. 7 and Supple-
mentary Figs. 8–10). We found that the alleles with the strongest
evidence of protection tend to be at a lower frequency in non-
African populations than expected, given the genome-wide dis-
tribution (e.g., conditional rank of allele in European populations
given African allele count (rankEUR) < 0.5 for 10 of 12 regions
with BFavg > 10,000; 45 of 91 regions with BFavg > 1,000; based on
reference panel allele counts; Fig. 7a), consistent with the
hypothesis that these alleles have been maintained at a high fre-
quency in African populations by positive selection. However,
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this comparison provides extremely modest levels of evidence—
even for individual alleles where selection of this type is well
accepted. We similarly found modest evidence for within-Africa
differentiation (e.g., P= 3 × 10−3 against the null model of no
differentiation, for the 12 regions with BFavg > 10,000; P= 0.02
across 92 regions with BFavg > 1000, excluding all but one variant
within the HLA region; Fig. 7b, c). A further discussion of dif-
ferentiated loci is found in Supplementary Note 9.
These analyses add new weight to the hypothesis that malaria-
driven selection has played a polygenic role in shaping human
genomes in endemic populations. However, this evidence is
rather weak and it is equally clear that many of the most
differentiated alleles, including those within the HLA (e.g., HLA-
DPB*01; frequency range 25–54% in African populations; PXtX=
8.9 × 10−15), variants in CD36 (e.g., rs73711929, frequency range
2–20% in African populations; PXtX= 8.3 × 10−20), as well as
variants in regions associated with skin pigmentation58 (e.g.,
rs1426654; frequency range 83–99% in African populations; PXtX
= 2.5 × 10−15) are not associated with susceptibility to P.
falciparum malaria (Supplementary Fig. 11). Other selective
forces may have contributed to the evolution of these alleles59 and
in many cases these remain to be identified.
Discussion
This analysis identifies five replicable loci with strong evidence for
association with resistance to SM: HBB, ABO, ATP2B4, the gly-
cophorin region on chromosome 4 and a new locus between
MAP3K7 and EPHA7 on chromosome 6 whose causal
Fig. 5 The ATP2B4 association is driven by an erythrocyte-specific transcription start site. a Normalized RNA-seq coverage for (1) 56 cell types from
Roadmap Epigenomics29 and ENCODE, (2) human CD34+ hematopoietic stem and progenitor cells, and experimentally differentiated erythroid cells from
three biological replicates31, (3) ex-vivo differentiated adult and fetal human erythroblasts from 24 individuals32 and (4) experimentally differentiated
erythroid progenitor cells and circulating erythrocytes45. Coverage is shown across expanded regions of ATP2B4 exon 1, exon 2 including the putative
alternative first exon (located at 203,651,123–203,651,366) and the remaining exons. Throughout, red features are those lying within 500 bp upstream to
50 bp downstream of the alternative first exon. For Roadmap and ENCODE data, the plot reflects normalized coverage maximized across cell types in each
tissue group. For other cells, coverage is summed over samples and normalized by the mean across ATP2B4 exons. b ATP2B4 transcripts from the
GENCODE41 and FANTOM544 transcript models. c Posterior evidence for association with SM assuming a single causal variant. d Position of GATA1-
binding peaks28. e Location and size of the expanded regions shown against the full-length transcript, with GATA1-binding peaks shown. f Posterior
evidence for association with SM as in c and with mean corpuscular haemoglobin concentration (MCHC)36, assuming a single causal variant for each trait
separately. g Estimated effect of rs10751451 on each exon of ATP2B4, computed by linear regression against FPKM residuals after correcting for cell
development stage32, with 95% confidence intervals shown. For comparable visualization across exons, FPKM is further normalized by the mean across
samples at each exon. h Mendelian randomization analysis of SM and MCHC at 2130 ‘sentinel’ SNPs previously identified as associated with
haematopoetic traits36 with association results in our study. Points reflect the posterior effect-size estimates on SM (y axis) and MCHC (x axis),
conditional on the fitted bivariate Gaussian model of effect sizes. Variants are assumed to act independently. Blue solid and dotted lines and text show the
maximum likelihood estimate of the effect of MCHC on SM (ρ), its 95% confidence interval, and likelihood ratio test P-value against the null that ρ= 0.
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mechanism is unknown. The HBB, ABO and glycophorin asso-
ciations correspond to known phenotypic variants of human
RBCs, namely sickle cell trait and the O and Dantu blood group
phenotypes. Adding to previous work32, our analysis indicates
that the associated haplotype in ATP2B4 also has a specific effect
on erythrocyte function. The putative protective allele disrupts a
GATA1-binding site upstream of a TSS, which is only active in
erythroid cells, and thus reduces expression of this gene in ery-
throcyte precursors. This is reminiscent of the protective effect of
the Duffy-null allele against P. vivax malaria, which also involves
disruption of a GATA1-binding site causing erythrocyte-specific
suppression of the Duffy antigen receptor46,47, and it adds to
growing evidence that tissue-specific transcriptional initiation is
an important factor in determining human phenotypes60,61.
ATP2B4 encodes the main erythrocyte calcium exporter and the
associated haplotype has been experimentally shown to control
calcium efflux and hydration32,40. This is consistent with the
observed effects on red cell traits36 and with the hypothesis that
ATP2B4 modulates parasite growth within erythrocytes, perhaps
by affecting calcium signalling mechanisms that are essential to
several stages of the parasite life cycle62,63. In theory, this finding
raises the possibility of therapeutic blockage of ATP2B4 in ery-
throcytes without otherwise affecting physiology. Based on the
estimated effect and population frequency of the associated
haplotype, this might be expected to provide ~1.5-fold protection
against SM and be efficacious in the ~90% of individuals who do
not currently carry the protective homozygous genotype at this
locus. It is open to speculation whether this could lead to
worthwhile therapy in practice.
The five loci identified so far appear to explain around 11% of
the total genetic contribution to variation in malaria susceptibility
(Supplementary Fig. 4). It is possible that this estimate is con-
founded, e.g., by unusual LD patterns or by environmental factors
such as variation in underlying infection rates, and it should likely
be treated with caution. Nevertheless, it raises the question as to
why only five loci can be reliably detected at present. Selection
due to malaria has been sufficiently strong to maintain alleles
such as sickle haemoglobin at high frequency in affected African
populations64 (Fig. 7). However, it has evidently also led to
complex patterns of variation at malaria resistance loci. This is
exemplified by the emergence of haemoglobin C and multiple
haplotypes carrying sickle haemoglobin at HBB, and by copy
number variation observed at the alpha globin and glycophorin
loci14,65. In addition, there is evidence for long-term balancing
selection at the ABO66 and glycophorin67 loci, which may be
malaria-related. In theory, the simplest outcome for a strongly
protective allele is that it would sweep to fixation, but unlike for
P.vivax68 no sweep of a mutation providing resistance to P. fal-
ciparum malaria is known. Remaining protective alleles may
therefore have effect sizes too small to be subject to strong
selection, requiring large sample sizes to detect. GWASs of other
common diseases have shown the benefit of exceptionally large
sample sizes69–73 and, although there are many practical obstacles
to achieving this for SM, particularly as its incidence has fallen in
recent years due to improved control measures74,75, efforts to
collect new samples and to combine data across studies63 are
warranted. It is also possible that relevant alleles may have
become balanced due to pleiotropic effects, or be subject to
compensatory parasite adaptation—both scenarios that might
lead to maintenance of allelic diversity. Dissecting such signals is
naturally challenging for GWAS approaches and may require new
techniques, such as sequencing and joint analysis of host and
parasite genomes from infected individuals, to address.
Methods
Ethics and consent. Sample collection and study design was approved by Oxford
University Tropical Research Ethics committee (OXTREC), Oxford, UK (OXTREC
020–006). Local approving bodies are detailed in Supplementary Table 1. Further
information on policies, research and the consent process may be found on the
MalariaGEN website (http://www.malariagen.net/community/ethics-governance).
Collection and processing of whole-genome sequence data. Blood samples
were collected from a total of 773 individuals from Gambia, Burkina Faso,
Cameroon and Tanzania, and sequenced to an average of 10× coverage on the
Illumina HiSeq 2000 platform at the Wellcome Sanger Institute, using 100 bp
paired-end reads. In addition, one Gambian trio was additionally sequenced using
three alternate library preparation methods (low-quantity and whole-genome
amplification pipelines) for a total of 782 sequenced samples. Sequence reads were
Evidence for association
(log10 Bayes factor)
R
an
k E
UR
3 4 5 6 7 8 ...9
Evidence for association
(log10 Bayes factor)
3 4 5 6 7 8 ...9
10%
30%
50%
70%
90%
a
HbS
O
rs4951377
(ATP2B4)
rs567544458
(FREM3/GYP)
rs62418762
0
1
2
3
4
0
1
2
3
4
−
Lo
g 1
0P
Xt
X
−
Lo
g 1
0P
Xt
X
−Log10PXtX(expected)
b
HbS
rs567544458
(FREM3/GYP)
rs2523650 (HLA)
rs56292300 (AP2B1)
rs62380051 (TRIM36)
rs9940464 (CDH13)
rs549107698 (STX1A)
0.0 0.5 1.0 1.5 2.0
c
Fig. 7 Empirical evidence for frequency differentiation of the most associated alleles. a The European population rank (rankEUR, y axis) plotted against
the evidence for association (log10 BFavg, x axis) for the protective allele at each of the 91 lead variants satisfying BFavg > 1000 and having assigned
ancestral allele. For each variant with an estimated protective (respectively risk) derived allele A, rankEUR is defined as the proportion of alleles genome-
wide having lower or equal (respectively greater than or equal) count than A in European populations, conditional on having the same frequency in African
populations, estimated in reference panel populations. On average, rankEUR is expected to be equal to 50% (red dashed line). Points are labelled by the rsid
and nearest or relevant gene(s), or by functional variant where known; O refers to rs8176719, which determines the O blood group. b Evidence for within-
Africa differentiation (PXtX, y axis) plotted against the evidence for association (log10 BFavg, x axis) for each of the 92 lead variants satisfying BFavg > 1000,
after removing all but rs2523650 from within the HLA region. PXtX is computed from an empirical null distribution of allele frequencies learnt across control
samples in the seven largest African populations (Supplementary Figs. 8 and 9). c Quantile–quantile plot for PXtX across the top 92 regions in b. Source
data are provided as a Source Data file.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-13480-z ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:5732 | https://doi.org/10.1038/s41467-019-13480-z | www.nature.com/naturecommunications 9
mapped to the GRCh37 human reference genome with additional sequences as
modified by the 1000 Genomes Project (hs37d5.fa), using BWA76 with base quality
score recalibration and local realignment around known indels as implemented in
GATK77.
We used GATK UnifiedGenotyper to identify potential polymorphic sites on
autosomal chromosomes, using all 782 samples as well as the 680 samples of
African ancestry from the 1000 Genomes Project, and running in 50 kb chunks.
GATK VQSR was used to separately filter SNPs and indels. For SNPs, we included
three training sets: HapMap SNPs, SNPs on the Omni 2.5 M array and 1000
Genomes Phase 3 sites. For indels we used the ‘Mills’ training set as recommended
in the GATK documentation. We based filtering on read depth, mapping quality,
quality by depth, the MQRankSum and ReadPosRankSum measures of bias in
reference vs. alternate allele-mapping quality or read positions, and tests for strand
bias and inbreeding coefficient. We filtered variants applying a sensitivity setting of
99.5% (--ts_filter_level 0.95) for SNPs and 95% for INDELs (--ts_filter_level 0.95).
We further restricted to biallelic sites.
We computed genotype likelihoods at all sites passing the filter described above
and sites in 1000 Genomes Project Phase 3 reference panel using GATK
HaplotypeCaller. We then used BEAGLE v4.078 to generate genotype calls from the
genotype likelihoods. We ran BEAGLE in windows of 50,000 SNPs, including trio
information for Gambian samples. Due to the observed long runtimes when
sampling trios, we specified trioscale= 3 when running BEAGLE to reduce
computation times. We then concatenated results across chromosomes.
To estimate haplotypes, we first removed variants not present in the 1000
Genomes Phase 3 panel or variants that had alleles differing from those in the 1000
Genomes Phase 3 panel, using the ‘check’ mode of SHAPEIT279. We then used
SHAPEIT2 to phase each chromosome. We included trio information for Gambian
samples, specified a window size of 0.5 (--window), an effective sample size of
17,469 (--effective-size), 200 model states (--states), included 1000 Genomes Phase
3 haplotypes in the phasing process (--input-ref) and used the hapmap-combined
recombination map in build 37 coordinates (-M).
To construct a combined imputation reference panel, we first removed repeated
samples and then combined phased haplotypes at the remaining samples with
those from the 1000 Genomes Project phase 3 panel. The final panel contains
77,931,101 variants and 3277 samples, of which 773 are from our set of sequence
data and 2504 are from the 1000 Genomes panel. In total, the panel includes 1434
individuals with recent African ancestry (including 157 African American samples)
and non-African samples as previously described11.
Collection and genotyping of GWAS data. Cases of SM were recruited on
admission to hospital as part of ongoing studies by local investigators (Supple-
mentary Table 1). SM phenotypes were ascertained in a standardized manner
across all samples using definitions as per WHO guidelines23 for CM (Blantyre
coma score < 3 in children or Glasgow coma score < 11 in adults), SMA (hae-
moglobin < 5 g/100 mL or haematocrit < 15%) and other malaria-related symptoms
(here referred to as ‘other SM’). The distribution of these phenotypes between
countries is summarized in Supplementary Fig. 5. Control samples representative
of the ethnic groups of the cases were collected from cord blood or in some study
sites from samples from the local population5. For our main discovery and repli-
cation analyses, we maximized sample size by including all samples collected as
cases and controls. For specific estimation of effect sizes (Fig. 4), we restricted to a
‘strict’ definition of case status defined as having positive measured parasitaemia.
Further details of this study have been published previously5 and information on
policies, research and the consent process may be found on the MalariaGEN
website (http://www.malariagen.net/community/ethics-governance).
Sample genotyping was performed at the Wellcome Sanger Institute using the
Illumina Omni 2.5 M platform. Genotype calling was performed using three
genotype calling algorithms (Illumina Gencall, GenoSNP80 and Illuminus81) and
we formed final genotype calls by taking the consensus of the three algorithms, or
of two algorithms where the third algorithm reported a missing call, as used
previously7. Genotypes for which a discrepant call were made were treated as
missing.
We used strand information from array manifest files provided by Illumina and
those from a remapping process implemented by William Rayner at the Wellcome
Centre for Human Genetics, Oxford, to determine the strand of each assay on each
of the two genotyping platforms used. We omitted variants where mapping or
strand information was discrepant, with some adjustments for Omni 2.5 M ‘quad’
array as described below. In addition, we annotated each variant with the reference
allele as taken from the build 37 reference sequence FASTA file. We used these data
with QCTOOL (see Code availability) to realign study genotypes. The resulting
‘aligned’ datasets are encoded so that the first allele reflects the reference allele, the
second allele the non-reference allele and all alleles are expressed relative to the
forward strand of the reference sequence, simplifying downstream analysis.
As a sanity check, we plotted the estimated frequency of each non-reference
allele against the frequency in the closest reference panel group in each
populations. The Kenyan dataset (which was typed using the Omni 2.5 M quad ‘D’
version manifest) showed a substantial number of SNPs with frequencies obviously
wrongly specified. Comparison of the flanking sequence and alleles reported in the
manifest file identified 18,763 SNPs that had alleles coded incorrectly in the
manifest file. We repaired fixed these SNPs by recoding these alleles, making them
consistent with the flanking sequence, the more recent ‘H’ version of the manifest,
and the Omni 2.5 M ‘octo’ chip manifest. We also updated the positions of 495
SNPs annotated as lying on the pseudo-autosomal part of the X chromosome (Chr
= ‘XY’ in the Illumina manifest) but with position= 0. We applied these updates,
repeated the alignment process for Kenya, and regenerated the frequency plot. A
small number of SNPs in each population still show distinct frequencies compared
with reference panel data (Supplementary Fig. 13).
Sample quality control. We used QCTOOL to compute the proportion of missing
genotype calls and the average proportion of heterozygous calls per sample, and the
average X channel and Y channel intensities across autosomal chromosomes for
each sample. Values were averaged over a subset of SNPs (‘the quality control (QC)
SNP set’) chosen to have low missing rates in all populations. We then ran
ABERRANT82 to identify individuals with outlying mean intensities separately in
each population. Considerable variation in the spread of quality between popula-
tions was observed and we picked population-specific values of the ABERRANT
lambda parameter based on visual inspection of the plots. We also manually
adjusted the ABERRANT-derived exclusions to include a small number of samples
in each population, which were observed to visually cluster with the main set of
included samples, but called as outlying by ABERRANT. We then plotted logit
(missing call rate) against average heterozygosity in each population. We excluded
samples with >10% missingness or heterozygosity outside the range 0.2–0.4 in
African populations, below 0.175 in Vietnam or below 0.13 in PNG outright
computed the QC SNP set. We then applied ABERRANT to the remaining non-
excluded samples choosing a value of the lambda parameter per population based
on inspection. As for intensity outliers, we specifically included some groups of
samples visually clustering with the main group of samples but called as outlier by
ABERRANT. We plotted heterozygosity against missingness annotating the
removed samples. Supplementary Figs. 14 and 15 show mean intensity, missing-
ness, and heterozygosity, computed across all variants, with excluded samples
annotated.
The above process results in a set of 18,515 samples that appear to be relatively
well genotyped across the autosomes. In addition, for some purposes described
below, we used a smaller set 17,664 samples (referred to as the ‘conservative’ set of
samples) obtained by repeating the above process with more conservative values of
the ABERRANT lambda parameter.
Almost all samples had sex determined by direct genotyping of amelogenin
SNPs5. To confirm the assigned sex, we plotted overall intensity from the Illumina
chip (X channel plus Y channel intensity) averaged across the X chromosome,
against overall intensity averaged across the Y chromosome (Supplementary
Fig. 16). We then modelled these mean intensities as drawn from a bivariate
normal distribution, with separate mean and covariance parameters in males and
females. A small number of samples were observed to lie near a point consistent
with female-like intensity values on the X chromosome but male-like intensity
values on the Y chromosome; this could potentially indicate males with an extra
copy of the X chromosome and we therefore further included an additional ‘mixed’
cluster with parameters derived from the male and female clusters on the X and Y
chromosome, respectively, and assuming no covariance between X and Y
chromosome intensities. We used the amelogenin SNP-based assignments and the
intensities for the conservative samples set to estimate the model parameters. Based
on the fitted model we then probabilistically assigned sex to all samples using Bayes
rule:
P sexjintensitiesð Þ / P intensitiesjsexð Þ´ P sexð Þ ð1Þ
where the first term on the right is computed using the bivariate normal model
described above and the second represents a prior probability on the sample sex.
We normalize the formula under the assumption that every sample is either male,
female or ‘mixed’. We specified a 1% prior probability of ‘mixed’ sex and equal
prior probability of 49.5% on each of the male and female clusters. Finally, we
assigned each sex having at least 70% posterior probability and treated the sex of
other samples as uncalled. Of the 18,515 samples in the QC set, 20 had mixed or
missing sex by this assignment, whereas 38 had assignment discrepant with the
amelogenin-determined sex. We removed samples with mixed or missing sex from
downstream analyses.
To identify relationships between samples, we used QCTOOL to compute a
matrix of pairwise relatedness coefficients in each population. To do this, we first
chose a subset of SNPs using a preliminary version of the SNP QC process
described below and used inthinnerator (see Code availability) to thin this set of
SNPs to lie no closer than 0.02 cM apart in the Hapmap-combined recombination
map. We additionally excluded SNPs from regions of known associations, the
region chr6:25,000,000–40,000,000, which contains the HLA, and the region of the
common inversion on chromosome 8. We used QCTOOL with the resulting set of
157,085 SNPs to compute the normalized allele sharing (‘relatedness’) matrix R=
(rij) where rij reflects the correlation in genotype between sample i and j,
normalized by variant frequency. The number rij may be treated as an estimate of
relatedness with values near 1 reflecting identity and values near 0 reflecting
unrelated samples, relative to the average relatedness in the population83,84.
For each pair of samples with relatedness > 0.75, we noted the sample with the
highest rate of missing genotype calls. A total of 538 samples were identified in this
way, the majority of which were from the Malawi and Kenya datasets, and likely
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reflect duplicate genotyping. We removed these samples from the datasets. For
each remaining pair of samples with relatedness > 0.2, we again noted the sample
with the highest rate of missing genotype calls; these represent samples that are
relatively closely related to other samples in the same study sample. A total of
801 samples were identified in this way. These samples were retained in the dataset
for phasing and imputation, but excluded from PC analysis and downstream
association testing.
We computed PCs by taking the eigendecomposition of R and plotted PCs in
each population. Based on visual inspection of these plots, we further identified a
total of 40 samples outlying on any of the first 10 PCs. We recomputed R and the
PCs after excluding these individuals, to produce a set of PCs for association
analysis. PCs were observed to correlate with population structure (as represented
by the reported ethnicity) and in some populations with case/control status and/or
with technical factors such as missing genotype call rates.
In total, following our sample QC process, 17,960 samples passed QC criteria,
had non-missing/non-mixed sex assignment and were not identified as duplicates
as described above. We took all of these samples through to the phasing and
imputation as described below. Of these samples, a total of 17,056 samples were
identified as not outlying on PCs, not closely related and having assigned case/
control status, and were included in downstream analyses. Supplementary Table 3
summarizes the sample QC.
SNP quality control. We observed study sample sets to vary considerably in
quality of typing (as well as in size), with the two smallest African sets (Mali and
Nigeria) and, to a lesser extent, Malawi having higher missing data rates and Kenya
having lower rates (Supplementary Fig. 17). Inspection of cluster plots suggests that
the higher missing rates are largely due to higher levels of noise in intensity values
for these populations.
We based SNP QC on several metrics computed separately in each population:
the estimated minor allele frequency (MAF), the proportion of missing genotype
calls (missingness), a P-value for Hardy–Weinberg equilibrium (HWE)85
computed in control samples (PHWE), a plate test P-value against the null model
that genotypes are uncorrelated with the plate on which each sample was
genotyped (Pplate) and a recall test P-value, which compares the genotype
frequencies with frequencies after a re-calling process based on the estimated
cluster positions across populations. The plate test was implemented using a
logistic regression model treating the genotype as outcome and an indicator of the
96-well plate on which the sample was supplied for genotyping as a predictor in
each population, and including case/control status and an initial set of five PCs as
covariates. For each SNP we computed a likelihood ratio test P-value for the
inclusion of plate as a predictor. The recall test was motivated by the observation
that some otherwise well-typed SNPs were poorly genotyped in individual
populations and was implemented as follows. We first used intensities and
genotype calls for the ‘conservative’ sample set to re-estimate the positions of
genotype clusters at each SNP in each study population using QCTOOL, fitting a
multivariate t-distribution with 5 degrees of freedom to each genotype cluster. For
each SNP in each target population, we then re-called genotypes using intensities
based on a mixture of the cluster positions learned in all other populations. We
used Fisher’s exact test to compute a p-value against the null that the frequency in
the original and re-called genotypes were the same.
We used association test statistics computed under a general logistic regression
model, including additive and heterozygote parameters, as a guide to choosing
appropriate thresholds for the above metrics. Specifically, we tested for association
with SM, including five PCs as covariates in each population. For the given QC
criteria, we plotted association test results annotating QC fails, along with qq plots
for the variants passing QC. In choosing thresholds, we were motivated by the
observation that the combination of consensus genotype calling (which is relatively
conservative in calling genotypes) with statistical phasing across populations would
likely produce a high-quality set of haplotypes for downstream inference. We
therefore aimed to produce a single set of SNPs with high-quality data across
populations for input to the phasing process. We chose a set of criteria applied to
the nine largest sample sets to compute a list of SNPs to include. We removed SNPs
with missingness >2.5% in Kenya and PNG, >5% in Gambia, Burkina Faso, Ghana,
Cameroon and Vietnam, and >10% in Malawi and Tanzania. We also excluded
SNPs with P < 1 × 10−20 for HWE, P < 1 × 10−3 for the plate test and P < 1 × 10−6
for the recall test in each population. Finally, we included each of the remaining
SNPs that was at MAF > 1% in at least two populations and passed the above
thresholds in all nine populations considered. Data from the Mali and Nigeria
populations, which had the lowest sample counts (484 and 133 samples,
respectively) and empirically lower rates of high-quality genotyping
(Supplementary Fig. 17), was not used to inform the SNP selection process. The
criteria above were observed to lead to essentially uninflated association test
statistics (Supplementary Fig. 18). In particular, we noted that a set of SNPs close to
the ends of chromosomes were excluded by these criteria; more information on this
is provided in Supplementary Note 2 and Supplementary Fig. 19.
SNP QC on the X chromosome was performed as for autosomes with the
following adjustments. We excluded the pseudo-autosomal region (defined as
variants with position <2,699,520 or >154,931,044; this region contained ~400
typed SNPs). We also observed elevated rates of males called as heterozygous
within the X transposed region (defined as chrX:88,457,462–92,374,313) and
excluded this region as well. Approximately 3400 SNPs were removed this way. In
computing summary statistics for males, we treated all heterozygous calls as
missing and homozygous calls as the corresponding hemizygous calls. We applied
the SNP missingness threshold and the plate test separately in males and females;
we replaced the HWE test with a test of difference in frequency between males and
females (based on a likelihood ratio test P < 1 × 10−6). We did not implement the
recall test for X chromosome SNPs.
Finally, we plotted cluster plots for all SNPs with genotypic association test P <
1 × 10−5 and manually excluded those with obviously problematic cluster plots.
Some SNPs are targeted by duplicate assays on the Illumina Omni 2.5 M array and
for these SNPs we excluded the assay showing the highest missingness, on average,
across populations. We also removed SNPs present on only one of the ‘quad’ and
‘octo’ platforms. Finally, we merged data for SNPs passing QC across populations
using QCTOOL for input to phasing. Supplementary Table 4 summarizes the
number of SNPs excluded by each criteria and the final QC set.
Phasing and imputation. We used SHAPEIT279 to jointly phase the 17,960 sam-
ples passing QC. In detail, we ran SHAPEIT2 on each chromosome separately
specifying an effective sample size of 17,469 and 200 copying states, and using the
HapMap combined recombination map. As above, we note that in addition to
phasing, SHAPEIT2 imputes missing genotypes at typed SNPs with missing data,
so that the output of this step contains hard-called phased genotypes with no
missing data. Following phasing we recomputed PCs across all populations, across
African populations, and in each population separately, using phased genotypes.
These PCs are shown in Fig. 1 and Supplementary Fig. 2.
We used IMPUTE2 (v2.3.2)86 to impute genotypes at all variants present in the
combined reference panel. To do this efficiently, we split the data into subsets of
500 samples and split the genome into a total of 1456 chunks of 2 Mb each. We ran
IMPUTE2 in each chunk and sample subset specifying a buffer region of 500 kb
and an effective population size of 20,000. Finally, we used QCTOOL to merge
imputation chunks across sample subsets and across chunks, encoding the results
in BGEN format87. For post-imputation analysis, we additionally merged all
impute ‘info’ files across chunks and sample subsets into a single file. We also
repeated imputation using the 1000 Genomes Phase III reference panel (as
available from the IMPUTE2 website 3 August 2015) using the same settings
throughout.
To assess per-variant imputation performance, we focused on ‘type 0 r2’ (which
measures correlation between input genotypes and re-imputed genotype dosages),
which we refer to here as accuracy. We plotted mean accuracy in 1% MAF bins for
each subset of samples imputed (Supplementary Fig. 1). We also plotted the
proportion of variants meeting a given accuracy threshold for lower-frequency
(<10% MAF) and higher-frequency (10–50% MAF) variants. Under the
assumption that untyped variants behave similar to typed variants, these plots
suggest that a substantial proportion of variation in the genome is imputed to high
accuracy using this panel. We additionally computed the mean difference in
accuracy, within MAF bins, for each imputation sample subset (Supplementary
Fig. 1). We used the per-sample imputation results output by IMPUTE2 to
compare imputation performance across ethnic groups. IMPUTE2 outputs an
accuracy measure (also called type 0 r2, which we refer to as per-sample accuracy)
for each sample for each imputation chunk, reflecting the correlation between
input genotypes and re-imputed genotype dosages across variants within each
chunk. We plotted the distribution of per-sample accuracy, averaged across
chunks, for samples in each of the largest ethnic groups in our data (Fig. 1).
To further investigate the effects of additional African reference panel samples
on imputation performance, we constructed a joint dataset consisting of phased
haplotypes at all 17,960 study individuals and all 3046 reference panel individuals,
subsetted to the overlapping set of 1,492,601 SNPs. For each pair (S,P) of a study
panel haplotype S and a reference panel population P, we computed the proportion
of 1Mb chunks such that the closest reference panel haplotype to S lies in P.
Proximity was measured by absolute number of differences with ties broken by
randomly choosing one of the closest haplotypes. We averaged the proportions
over samples in each study ethnicity; these proportions are plotted in Fig. 1c.
Imputation of HLA and glycophorin alleles. We used HLA*IMP:0250 to impute
HLA classical alleles for all study samples. We used the unphased, post-QC set of
genotype calls across populations in the region chr6:28Mb-36Mb as input. This
version of HLA*IMP outputs imputed diploid allele calls and posterior prob-
abilities for alleles at two-digit and four-digit resolution, and uses an allele naming
scheme that is similar to the pre-2010 IPD-IMGT/HLA naming convention. For
downstream analysis, we split HLA*IMP output into per-allele posterior prob-
abilities. Specifically, for each allele we computed the posterior probability of zero,
one or two copies of the allele, against all other alleles at the locus, from the
HLA*IMP output. We encoded this data in the GP field of a VCF file with one row
per allele. This functionality may be generally useful and is implemented in
QCTOOL. For reference purposes, we assigned each allele to the midpoint of the
corresponding gene.
We used IMPUTE2 to impute genotypes from a previously published reference
panel of SNPs, indels and large copy number variants (CNVs) in the glycophorin
region on chromosome 414. We based our imputation on the phased set of
haplotypes, but to avoid potential issues with phasing in this region we treated
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these genotypes as unphased. We then ran IMPUTE2 in 2Mb chunks across a
10Mb region surrounding the glycophorins, specifying 1000 reference panel
haplotypes, a 500 kb buffer region, an effective population size of 20,000, and using
the HapMap combined recombination map. As previously14, we excluded SNPs in
the region of segmental duplication when imputing CNV calls.
Association testing. We used SNPTEST (see Code availability) to test each
typed or imputed variant for association with SM status in each study popula-
tion. Specifically, for each population we ran SNPTEST for each of the 2 Mb
chunks output by imputation, including either 0, 2, 5 or 10 population-specific
PCs as covariates and under additive, dominant, recessive, heterozygote and
general models of association. For the main analyses presented here, we used
the versions based on including five PCs. A total of 17,056 samples had PCs
and assigned case/control status, and were included in association analyses.
We tested under additive, dominant, recessive and heterozygote inheritance
models.
To test association with the main SM subphenotypes in our data—namely CM
and SMA, and other SM cases (OTHER)—we extended SNPTEST to perform
maximum likelihood inference for multinomial logistic regression. A full
description of this method is presented in Supplementary Note 6. In brief, in this
framework, the likelihood is parameterized by the log odds of each case phenotype
(CM, SMA or OTHER) relative to the baseline phenotype (CONTROL), for the
genotypic predictor along with other covariates. The method produces maximum
likelihood estimates of these parameters and estimated parameter SEs and
covariances. Overall evidence for association can then be assessed by computing a
likelihood ratio test statistic and associated P-value, against the null model where
all genetic effect-size parameters are zero. In addition, for each case phenotype we
compute a Wald test statistic and P-value against the null model that the genetic
effect on that phenotype is zero. Of the 17,056 samples included in association
testing, 537 had no subphenotype assignment or were assigned as having both CM
and SMA phenotypes. For simplicity we excluded these samples from the genome-
wide test against subphenotypes. We tested under additive, dominant, recessive and
heterozygote inheritance models.
We additionally tested variants on the X chromosome using a logistic regression
model including sex as a covariate and treating male hemizygote genotypes in the
same way as homozygous females.
Genome-wide meta-analysis. To efficiently meta-analyse the association results,
we further developed our software package BINGWA7 (see Code availability).
BINGWA is written in C++ and takes a list of SNPTEST files, along with options
that control variant filtering and output, and computes meta-analysis results using
both frequentist and Bayesian methods. Per-population results for each variant
were included in meta-analysis if the minor allele count (or for non-additive tests,
the minor predictor count as defined below) was at least 25, the IMPUTE info was
at least 0.3 and no issues were reported with model fitting. For the non-additive
tests, we defined the minor predictor count as the minimum of the expected
number of individuals having the effect genotype (e.g., AB or BB for dominant
model of the B allele, BB for recessive model, etc.) and the number having the
baseline genotype (e.g., AA for a dominant model of the B allele, AA or AB for
recessive model, etc).
For each case/control or subphenotype test, we computed a frequentist fixed-
effect meta-analysis estimate βmeta, its variance–covariance matrix Vmeta and
overall meta-analysis P-value as described in Supplementary Note 7. For
subphenotype tests, βmeta is three dimensional (corresponding to joint estimates for
CM, SMA and other severe malaria cases); we additionally computed a Wald test
P-value for each estimated parameter.
To assess evidence for association under a more flexible set of models of
association, we used a Bayesian meta-analysis framework similar to that
described previously5,7,12. In brief, we implemented Bayesian inference using the
asymptotic or approximate Bayes factor approach88. This approach treats the
observed effect sizes (estimated by logistic or multinomial logistic regression in
each population) as arising from a set of true population effect sizes, together
with estimation noise that is represented by the SEs and parameter covariances
in each population. The ‘true’ population effects are modelled as being drawn
from a multivariate normal distribution with mean zero and a prior covariance
matrix Σ, which is chosen to represent a desired model of true effects. We write
this covariance in the form
Σ ¼ σPσ ð2Þ
where Ρ is a correlation matrix specifying the prior correlation in true effect sizes
between populations and/or between subphenotypes, and σ is a scalar (or, in the
general case, a diagonal matrix), which determines the prior variance of effect
sizes, and thus the overall magnitude of modelled true effects.
Given the vector of per-population estimates β and the parameter covariance
matrix V, a Bayes factor for the model encoded by Σ can now be computed as a
ratio of multivariate normal densities
BF ¼ MVN β; 0;Vþ Σð Þ
MVN β; 0;Vð Þ ð3Þ
Different choices of Σ correspond to different assumptions about the underlying
true effect sizes. The true pattern of effects is unknown, so we assess evidence under
a collection of plausible assumptions Σ1, Σ2, … by computing the model-averaged
Bayes factor
BFavg ¼ w1BF1 þ w2BF2 þ ¼ ð4Þ
in which BFi is the BF computed using prior covariance Σi and the prior weights wi
are chosen to sum to 1. The specific choices of prior correlation matrix Ρ and
weights w used for our primary analysis are described below and in Supplementary
Table 5. For each choice of correlation matrix Ρ, we computed the BF for that
model as an equally weighted average over four values of σ—namely 0.2, 0.4, 0.6
and 0.8. We also repeated all analyses under additive, dominant, recessive and
heterozygote modes of inheritance with prior weights 0.4, 0.2, 0.2 and 0.2,
respectively.
For case/control tests we considered the following models of effects across all
populations:
fixed effects (all off-diagonal entries of Ρ set to 0.99)
correlated effects (all off-diagonal entries of Ρ set to 0.9)
independent effects (all off-diagonal entries of Ρ set to 0)
structured effects (Ρ estimated from the correlation in allele frequencies
genome-wide)
We placed a total of 60% prior weight on fixed and correlated effects and 4%
prior weight on each of independent and structured effects. In addition to effects
across all populations, we included models of effect restricted to population
subgroups. Specifically, we focused on the following groupings:
● West African populations (Gambia and Mali, or Gambia, Mali, Burkina Faso
and Ghana)
● West and Central West African populations (Gambia, Mali, Burkina Faso,
Ghana, Nigeria and Cameroon)
● Central West African populations (Burkina Faso, Ghana, Nigeria and
Cameroon)
● Central and East African populations (Nigeria, Cameroon, Malawi, Tanzania
and Kenya)
● East African populations (Malawi, Tanzania and Kenya)
● All African populations (Gambia, Mali, Burkina Faso, Ghana, Nigeria,
Cameroon, Malawi, Tanzania and Kenya)
● Non-African populations (Vietnam, PNG)
Population subset models were implemented by setting the value of σ to
0.001 for non-associated populations. These subsets are chosen to correspond to
geographical groupings, as well as to groups apparent along the first PC of African
populations (Fig. 1e), and such that no group has fewer than 2000 samples. We
placed 4% prior weight on each of the eight groups, for a total weight of 1
(Supplementary Table 5).
In our results files and in Supplementary Data 1, these population groupings are
denoted by a string of eleven 0s and 1s, with populations ordered west–east as in
Fig. 1a, and a 1 indicating that the effect is assumed nonzero in the corresponding
population. For example, the model fix:11111111100 denotes fixed effects across all
African populations.
We placed 80% of prior mass on case/control effects as described above, but also
considered effects that vary across subphenotypes (CM, SMA and other SM), as
well as effects that are only present for only two or one of the subphenotypes
(Supplementary Table 5). Specifically, we considered:
Effects on all three subphenotypes (between-phenotype entries of Ρ set to
0.9 or 0).
Effects on two of three subphenotypes (σ set to 0 for one phenotype, between-
phenotype entries of Ρ set to 0.9 or 0).
Effects restricted to one subphenotype (σ set to 0 for two phenotypes)
We assigned these categories prior weights of 8%, 6% and 6%, respectively. To
avoid spurious results, when conducting subphenotype meta-analysis we assumed
that effects were fixed across populations; specifically, between-population within-
phenotype entries of Ρ were set to 0.99 and between-population between-
phenotype entries of Ρ were set to 0.99 times the assumed between- phenotype
correlation specified above. The results of using the set of models and prior weights
described above to compute BFavg are shown in Fig. 2.
To allow further assessment of the dependency of BFavg on the model
assumptions, the full meta-analysis output produced by BINGWA includes
A full set of BFs, computed under a larger set of models, including those making
up BFavg.
The model with the highest BF.
The model with the highest posterior weight (i.e., highest BF after the
weighting) and the model with second highest posterior weight.
A per-population BF reflecting the evidence from each individual population
(as for BFavg, these are computed by model averaging over parameters σ= 0.2,
0.4, 0.6, 0.8. For subphenotype tests we assume independence between effects in
different subphenotypes).
Meta-analysis effect-size estimates and SEs, computed under the frequentist
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fixed-effect model, with associated P-values.
A summary of the set of populations and number of samples that were included
in meta-analysis.
Additional information, including genotype counts and INFO scores, taken
from the SNPTEST result files.
In our implementation, BINGWA was used to store meta-analysis for each
mode of inheritance in a sqlite database, with results indexed by variant position
and identifiers, and we used sqlite features to construct the final meta-analysis.
Interpretation of the Bayesian model average. Conditional on the set of prior
assumptions outlined above, the Bayes factor can be interpreted directly in terms of
a prior odds of association by the formula
Posterior odds ¼ prior odds ´BFavg ð5Þ
In the absence of other information about a given genetic variant, plausible
values of the prior odds might be in the range 10−5–10−7 as described
previously15,89. For a Bayes factor of 1 × 105, this would therefore give posterior
odds of association between one and one-hundredth (i.e., posterior probability of
1–50%). This computation thus reflects our belief about the top signals in our data,
namely, that there is overwhelmingly strong evidence for signals at HBB, ABO,
ATP2B4 and at the glycophorin region (for which BFavg > 5 × 107), good evidence
at ARL14 and rs62418762 (BFavg > 5 × 106) and some evidence at further loci
among the top 12 (BFavg > 1 × 105). Except for the association at ARL14, these
observations are further reinforced by the replication data (Fig. 2c).
Given the assumptions underlying BFavg, the relative evidence for different
models can also be interpreted as in Fig. 2. For example, at rs8176719 since the
Africa-only model has prior weight 0.04 × 0.8= 0.032 (averaged over mode of
inheritance), the observation of 90% posterior probability on an Africa-only model
(Fig. 2) reflects the fact that Bayes factor for this model is around 280 times larger
than under any other model. Specifically, under a dominance model of case/control
effects, the computed Bayes factors are 4.5 × 1017 and 1.2 × 1020 for effects across
all populations and across Africa only, a relative difference of 265. (The Bayes
factor for fixed effects across Africa and Vietnam combined is 2.6 × 1019, although
we did not include this model in BFavg).
The BFavg gives a direct measure of evidence for association present in the data
conditional on the assumptions. However, in the context of GWAS in which many
variants are tested, it is also useful to understand the distribution of Bayes factors
that would be observed by chance if no nonzero effect were present. A general way
to do this is to treat the BFavg as a test statistic and to compute or estimate its null
distribution90. To do this for rs62418762, we adopted a simulation-based approach
in which we first estimated the frequency of the three genotype classes in each
population, across case and control samples. Next, we conducted multiple rounds
of simulation. In each simulation we simulated genotype counts for controls and
for CM, SMA, OTHER and CM+ SMA cases in each population by sampling
genotypes from a multinomial distribution as
Genotype countsjphenotype; population  multinomialðN; f Þ ð6Þ
where N is the number of samples with the given phenotype in the population and
f is the three-vector of estimated genotype frequencies for the three genotype
classes in that population. Each simulation is thus performed by generating a 5 × 3
array of genotype counts in each population. We implemented the simulations in
R. For each simulation we then used the vcd package91 to compute the log-odds
ratios for all cases against controls and for each SM subphenotype against controls,
for each mode of inheritance, along with SE and covariances. We passed these
estimates into the meta-analysis pipeline described above for discovery data to
compute BFavg. Similar to the discovery analysis, to exclude spurious results due to
small counts, populations with minor allele count < 10 (for additive model tests) or
minor predictor count < 10 (for non-additive model tests) were excluded from
meta-analysis.
The procedure described above produces a simulated distribution of BFavg
under the null, conditional on observed genotype frequencies. In total, we
conducted 712,650,010 rounds of simulation, of which 5 had BFavg larger than the
observed BFavg for rs62418762. The distribution of resulting Bayes factors is
presented in Fig. 3c.
Bayesian replication analysis. The Bayesian framework outlined above naturally
extends to a discovery/replication setting; this is described further below and in
Supplementary Note 5.
Selection and interpretation of candidate regions. To identify a set of variants
with high-quality evidence, we first filtered variants based on minor allele count
and imputation quality as follows. In each population, we computed an effective
minor allele count (EMAC) by the formula
Effectiveminor allele count ¼ IMPUTE info ´minor allele count ð7Þ
where the minor allele count refers to the number of the less frequent allele seen in
that population. For imputed variants, this is the expected number given the
imputed genotype distribution. We then formed an overall EMAC by summing
this quantity across all 11 populations in our study (or, for variants where
individual populations were omitted from meta-analysis, across all populations
included in the meta-analysis). For downstream analyses, we considered all variants
with EMAC ≥ 250. This is a relatively relaxed criterion: e.g., for a variant with
IMPUTE info= 1 in each population, this corresponds to an overall MAF of 250/
(2 × 17,056)= 0.75%. Using the combined genome-wide reference panel, a total of
26,035,208 variants passed this filter.
We ranked the filtered list of variants in decreasing order of BFavg and used
inthinnerator to define a set of ‘lead’ variants and association regions. Inthinnerator
works by iteratively picking the variant with the highest rank as lead variant and
excluding all other variants in a recombination interval around the chosen variant.
We specified a recombination interval of 0.125 cM plus a margin of 25 kb on either
side of each lead variant, with distances determined by interpolating the HapMap
combined recombination map.
Association regions around HBB and around the glycophorin gene cluster on
chromosome 4 are especially extensive. We treated these regions specially, defining
them as the regions chr11:3.5 Mb–6.5 Mb and chr4:143.5 Mb–146Mb, respectively,
based on visual inspection of the association signal and we excluded these regions
from the inthinnerator region definition process. Including these regions, a total of
97 association regions contained a variant with BFavg > 1000 and are listed in
Supplementary Data 1.
To visually inspect regions, we created a set of plots showing the evidence for
association. Specifically, we created hit plots showing:
The association signal (log10 BFavg), colouring points by LD with the lead
variant computed using the African reference panel haplotypes and annotating
variants that were directly typed and included in our phased set.
Recombination rates from the HapMap combined recombination map.
Regional genes and pseudogenes, taken from the UCSC Genome Browser
refGene track downloaded on 9 June 2016.
A set of annotations reflecting functional information (described further below).
To annotate variants with functional information, we ran Variant Effect
Predictor27 from Ensembl tools release 75, to predict the functional consequence of
each typed and imputed variants within each association region using the
–everything flag. We additionally annotated variants with previously reported
association for traits from the NHGRI/EBI GWAS catalog36,38 and a previously
published GWAS of haematopoetic traits35, and with measured RNA expression
levels (processed as described below), transcription factor-binding sites, chromatin
state in erythrocyte precursors and other cells29–31, topologically associated
domains92 and reported eQTLs across cell types32–34.
For each lead variant, we also created forest plots showing, for each mode of
inheritance,
the effect-size estimate and confidence interval estimated in each population
the number of samples, variant frequency and IMPUTE info in each population
the frequentist meta-analysis results
a bar plot summarizing the Bayesian meta-analysis results
Forest plots for lead variants can be found in Supplementary Figs. 5 and 6. As
described above, we also produced and inspected cluster plots of typed variants
with evidence of association.
Analysis of RNA-seq data from erythrocyte precursors. We obtained raw RNA-
seq data from erythrocyte precursors31,93 from the Gene Expression Omnibus
(GEO) using the sra toolkit. In total, data on eight cell types was processed:
CD34+, BFU-E, CFU-E, early basophilic, late basophilic, proerythroblast, poly-
chromatic and orthochromatic erythrocyte progenitor cells, with three replicates of
each31,93. We also downloaded data on 12 fetal and 12 adult experimentally dif-
ferentiated erythroblasts reported by Lessard et al.32. To process these data, we
extracted FASTQ files from the SRA archives and mapped reads to the build
37 reference sequence using TopHat v2.0.14, using the Gencode v19 release of the
human reference sequence and gene annotations. For the Lessard et al.32 data, we
included the options --library-type fr-firststrand and --microexon-search to match
the original processing. We also downloaded RNA-seq data from circulating ery-
throcytes45 from the GEO. These data were aligned to the build 37 reference
sequence using bwa-mem76 and we marked duplicate reads using Picard (https://
broadinstitute.github.io/picard).
To visualize coverage profiles across ATP2B4, we restricted attention to reads
with mapping quality at least 50 and used bedtools genomecov94 to compute
coverage across the gene and across the genome. We plotted per-base coverage
divided by the total coverage across ATP2B4 exons, summed over samples within
each dataset and developmental stage (Fig. 5). To compute eQTL results in ATP2B4
exons in the 24 samples from Lessard et al.32, we computed fragments per kilobase
of transcript per million mapped reads (FPKM) in each exon as
FPKM ¼ #readsmapping to exon ´ 10
6
exon length in kb ´ total number of reads
ð8Þ
We then used a linear model to compute residual FPKM after regressing out the
developmental stage (fetal or adult)32. For comparison across exons, we
additionally standardized this residual FPKM (i.e., by subtracting the mean and
dividing by the SE across samples). We computed eQTL results by fitting a linear
model of genotype on the standardized, residual FPKM values.
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Analysis of ENCODE/Roadmap RNA-seq profiles. We downloaded normalized
RNA-seq coverage profiles for 56 cell types, representing 12 tissues and the
ENCODE cell lines, from the roadmap epigenomics browser29 at http://egg2.wustl.
edu. We used the stranded normalized coverage files and summed across the two
strand for visualization purposes (Fig. 5). To summarize coverage across tissues, we
used the tissue assignments in the ‘jul2013.roadmapData.qc - Con-
solidated_EpigenomeIDs_summary_Table.csv’ file and computed the maximum
per-base normalized coverage across all cells within each tissue across the ATP2B4
region. ENCODE cell lines were treated as a single group, except that we treated the
K562 cell line separately as it has an expression programme similar to
erythroid cells.
Generation and analysis of replication data. We selected SNPs for genotyping on
the Sequenom® iPLEX Mass-Array platform (Agena Biosciences, Hamburg,
Germany) as follows, following a similar protocol used previously5, based on a
preliminary version of the GWAS analysis described above. In brief, we identified
the 100 regions with the most evidence for association under a case/control model
of association, using inthinnerator to identify lead variants within regions. In each
region we considered up to five SNPs for replication, including the lead SNP and
others with substantial evidence for association. We further ranked regions using
BFavg restricted to non-case/control models of association and selected additional
SNPs making up to five in each region. We designed primer sets for these variants
omitting those in regions previously assayed5,7. Altogether, we designed two
multiplexes targeting 76 variants. We used these multiplexes to genotype all
samples collected in the project including discovery samples and additional sam-
ples in each population, which we used for replication. Three variants had >20%
missing genotyping rate across samples and were excluded from downstream
analysis, leaving data for 73 variants in 35 genomic regions. Genotype calls for
these assays, along with data for the SNPs previously assessed5,7 were combined in
a single database for downstream processing and we jointly processed all the
available data.
In total 37,571 individuals from this study had Sequenom genotyping available,
including 15,866 SM cases, 19,845 controls and samples collected as parents. For
data release purposes, we curated data across these individuals together with the
773 reference panel individuals (Fig. 1a) and 797 additional HapMap samples, and
previously published trio parents for which Sequenom typing was available, for a
total of 40,631 individuals. Most samples have a sex assignment by genotyping of
SNPs in the X-linked gene amelogenin5. A subset of 955 individuals were typed
from multiple blood samples in our database. For these individuals, we first
removed samples with discrepancies between the clinical record of gender and the
amelogenin-based sex assignment, and samples with missingness > 10% across all
SNPs for which typing had been conducted. We then merged genotypes across the
remaining samples for each individual to produce a single set of genotypes per
individual, by taking a consensus call across the repeat typing (i.e., treating
discordant calls as missing).
To provide a list of reliably typed individuals and variants, we excluded each
individual with >10% missingness (across included variants for which the
individual was typed) or with fewer than 50 called genotypes. Using the remaining
individuals, we computed per-variant missing data rates and labelled variants with
>10% missing data or fewer than 100 called genotypes for exclusion. We then
iterated this procedure, updating the list of included samples and variants for two
additional iterations, at which point no change in included samples or variants was
observed. This process produced a total of 37,732 individuals typed across 582
variants with low rates of missing data, including 15,024 SM cases and 18,556
controls.
We separated the curated individuals into discovery and replication cohorts as
follows. All individuals included in the GWAS phased genotype dataset were
marked as discovery individuals (a total of 17,267 individuals). The remaining
15,548 cases and controls who were not included in discovery data and who had an
assigned ethnic group as described in ‘Replication analysis’ below, were used for
replication analysis.
Validation of imputation results. For each imputed lead variant, we used
QCTOOL to compute the correlation between imputed genotypes and Sequenom-
typed genotypes, for all variants within 2 Mb of the lead variant, in discovery
samples within each population and across samples. We treated signals as poten-
tially replicable if a SNP with r2 > 0.75 with the lead imputed SNP across discovery
samples and typed at least 1000 replication samples were present (Supplementary
Data 1). We refer to such variants as Sequenom tags. A total of 25 regions among
those with BFavg > 1000 had a Sequenom tag. For some lead variants, multiple
Sequenom tags were available. Association test power depends linearly on sample
size and on the square of the correlation coefficient95. To assign a single ‘best tag’
for our primary replication analysis in each region, we ranked variants by the
product of r2 in discovery samples and the number of non-missing genotypes in
replication samples, and chose the highest-ranking SNP. Evidence at tag SNPs are
presented in Supplementary Data 1 and for the SNPs with the highest levels of
discovery evidence in Supplementary Figs. 5 and 6.
Replication analysis. We used SNPTEST to compute association test results using
the Sequenom genotypes, separately in discovery samples, replication samples and
across all analysis samples in each population. For replication analysis, we used
reported ethnic group as a covariate to control for potential confounding due to
structure in each population. Specifically, we removed samples with unreported
ethnic group and we grouped ethnic groups with fewer than 20 individuals into a
single category named ‘OTHER’; we then included the resulting groups as a fixed
effect in replication analysis. Variation in ethnic groups was present in all popu-
lations except for Malawi (where ethnicity information was not systematically
collected) and Burkina Faso (where all cases and controls were collected with
ethnic group ‘MOSSI’). We used BINGWA to compute a fixed-effect meta-analysis
across discovery data (based on imputed genotypes, as in our discovery scan) and
replication data (based on Sequenom typing) at each Sequenom-typed variant.
We extended the Bayesian analysis described above to a discovery/replication
analysis. A full description of this method can be found in Supplementary Note 5,
but in brief, this analysis produces a discovery BF (BFavg as described above), an
overall BF across discovery and replication samples (BFoverall), and a replication BF
(BFreplication), which is computed under the posterior effect-size distribution learnt
from discovery samples. These quantities satisfy
BFoverall ¼ BFavg ´BFreplication ð9Þ
Intuitively, BFreplication measures the evidence for association under the set of
models and effect-size distribution learnt from discovery samples. In practice,
requiring replication effect sizes to match the distribution learnt from discovery
may be too restrictive—e.g., this could happen if discovery effects sizes at chosen
SNPs are affected by Winner’s curse or because the distribution of phenotypes in
replication samples differs from that in discovery. We therefore assessed replication
data assuming true effect sizes in discovery and replication samples had a
correlation of 0.9. The effects of this assumption are discussed in Supplementary
Note 5. To report replication results where our chosen best tag is not the lead
GWAS variant, we report the BFavg for the lead variant and compute BFreplication
using the tag variant (Fig. 2c and Supplementary Data 1). We then compute
BFoverall as the product of BFavg and BFreplication.
For rs62418762, discovery data suggests a protective effect of the reference allele
on both CM and SMA susceptibility. We therefore also computed a replication P-
value for the alternative model ‘CM and SMA effects are protective’ for this SNP.
To do this, we simulated 10,000,000 parameter values under the null model, using a
two-dimensional normal distribution with mean zero and covariance set to the
estimated covariance matrix of the replication log-likelihood from meta-analysis.
We estimated the P-value as the proportion of simulated parameter values, which
lay in the negative quadrant and were more extreme than the observed quantities
(in the sense that they are points at lower density than the observed effect sizes
under this normal distribution.) This P-value is larger than the replication P-value
for CM alone and is reported in Fig. 3b.
For rs62418762, we additionally investigated between-population heterogeneity
in effects in discovery or replication populations by fitting a random-effect meta-
analysis model. We did not observe strong evidence for heterogeneity in CM, SMA
or OTHER subphenotypes either in discovery or replication data (likelihood ratio
test P > 0.05 against null model of no between-population heterogeneity), but we
note that power to detect heterogeneity is limited due to the relatively small
subphenotype sample counts in some populations (Supplementary Fig. 5).
Joint modelling of effects at associated loci. We reestimated the effect of the five
replicating variants on CM, SMA and nonspecific cases, as well as on samples
having both CM and SMA phenotypes, by fitting a joint model of effects across
variants and populations. In addition, two other variants (rs33930165, encoding
haemoglobin C (HbC), and rs8176746, which is indicative of A/B blood type, were
included as they are proximal to rs334 and rs8176719, respectively, and have been
previously implicated in malaria susceptibility5,53. To provide the most accurate
estimates, in this analysis we included only the ‘strict’ set of cases having a clinical
data record showing positive measured parasitaemia. We fit the model using the
nnet package in R and including five principal components from each population
and the study population indicator as covariates. We treated effects as additive,
except that variants with a clearly non-additive effect (as in Fig. 2c) were encoded
using the predicted protective dosage. Where ambiguous, we used the estimated
effect on CM to determine the protective allele and for this analysis we assumed
effects were fixed across populations. Results are shown in Fig. 4a. This analysis
suggested little evidence of association with rs8176746, indicating that observed
effects at this SNP are likely due to linkage disequilibrium with the O blood group
mutation rs8176719.
We used control samples to compute the frequency of the protective dosage (or
the allele frequency for variants with additive effects) for each variant across
populations. To visualize frequencies, we computed the minimum, maximum and
mean frequency for each variant across populations, and plotted frequencies as
circles with width proportional to the maximum frequency (Fig. 4b).
To investigate potential interactions between variants, we computed the
combined multilocus genotype for each sample across these variants, omitting
rs8176746. Combined genotypes with <25 samples were collapsed into a single,
‘other genotype’ category (not shown). We refit the model for SM across
populations using these multilocus genotypes as predictors and plotted the
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estimated effect sizes and confidence intervals against the expectation given the
estimates from individual variants and the assumption that variants contribute
independently to the log odds of disease. These estimates are shown in Fig. 4c.
Mendelian randomization with blood cell traits. We conducted MR analysis
(which, under restrictive assumptions, can provide evidence of a causal link
between two traits96) using summary statistics for 36 RBCs, white blood cells
(WBCs) and platelet traits previously published36. We treated each RBC, WBC or
platelet trait separately. For each trait T, we assumed a model of an effect of T on
SM, such that a unit increase in T increases the log odds of SM by a quantity ρ. If
this is the case then for any genetic variant affecting T we should have
βSM ¼ ρ ´ βT þ ζ ð10Þ
where βT and βSM denote the effect of the variant on T and on SM, and ζ represents
any additional effect of the variant on SM, over and above the effect through T.
Under the assumptions traditionally underlying MR analysis96, ζ= 0 and we
assumed this throughout.
We used a Gaussian likelihood formulation of MR97 under which the effect-size
estimates (β'T and β'SM) are assumed distributed around the true effects according
to the estimated SEs, as:
_βT
_βSM
 !
 MVN βT
βSM
;
se2T 0
0 se2SM
  
ð11Þ
and true effects are assumed to follow:
βT
βSM
 
 MVN 0; σ
2
T ρσ
2
T
ρσ2T ρ
2σ2T
  
ð12Þ
The latter equation reflects Eq. (10) when ζ= 0 and the assumption that effects
follow a Gaussian distribution.
To estimate ρ, we focused on the 2706 ‘sentinel’ variants identified as associated
with blood traits by Astle et al.36. A subset of 2130 of these variants were included
in the meta-analysis in our study after filtering by EMAC. We removed 89 variants
lying in any of the 95 regions of association containing a variant with BFavg > 1 ×
103 in our discovery analysis (including the ATP2B4 region). We treated the
remaining variants as independent and estimated ρ and σ2T by minimizing Eq. (12)
using the optim() function in R. To compute a P-value for model fit, we refit the
model assuming no correlation (ρ= 0) and computed the likelihood ratio P-value.
We visualized effect size and the model fit by plotting the effect-size estimates
on T and on SM across variants, overlaid with a line indicating the estimated value
of ρ and its 95% confidence interval. To avoid visualization problems stemming
from large estimates at variants with high SEs, we used effect-size estimates
regularized using a N(0, 0.1) prior in plots. These estimates are plotted in Fig. 5h
(for mean corpuscular haemoglobin) and Supplementary Fig. 12 (for all traits
tested).
For T=MCHC, our estimate of effect variance was σ2T= 0.0132. We plotted
the empirical distribution of observed effects overlaid with the Gaussian density
and observed some evidence that effects are overdispersed relative to the Gaussian
distribution with this variance. To verify that this did not adversely affect results,
we refit the model assuming a fixed prior value σ2T= 0.12, with similar results (ρ=
− 0.13, P= 7 × 10−3).
HLA region analysis. We tested for association and conducted meta-analysis for
imputed HLA alleles in the same way as described above for other variants. To
compare imputed HLA allele calls with previously published antigen frequencies,
we first computed a predicted antigen frequency for each allele as the proportion of
individuals heterozygote or homozygote for the allele. We plotted these frequencies
in control samples from each Gambian ethnic group against previously published
HLA Class I antigen frequencies (Table 1 of Hill et al.51). One pair of alleles were
particularly discordant (the B*15 allele, which is at relatively high frequency in our
imputation and the B70 antigen, which is at relatively high frequency in the ser-
otyped data). We used the IPD-IMGT/HLA dictionary to confirm that the B70
antigen is expressed by B*15 alleles and we therefore computed the combined B70/
B15 frequencies in Fig. 6b. For each ethnic group, we also computed squared
correlation between imputed and serotyped antigen frequencies.
To further assess HLA imputation, we selected 31 Gambian case samples, for
which both parents have previously been genotyped (EGA dataset
EGAD00000000019) for HLA typing based on available DNA quantities. These
samples were typed at 11 HLA gene loci through exon sequencing. Sequenced
regions included exons 2–4 of HLA-A, -B, -C, -DPB1, exons 2–3 of HLA-DPA1,
-DQA1, DQB1 and DRB1, and exon 2 of HLA-DRB3, -DRB4 and -DRB5. Typing
was performed by the Accredited Tissue Typing Laboratory at Addenbrooke’s
Hospital, Cambridge University Hospitals NHS Foundation Trust, using the
proprietary uTYPE software version 7 (Fisher Scientific, Pittsburgh, USA). The list
of possible ambiguous calls were minimized by using the ‘allele pair’ export
function in this software, which lists all possible and permissible allele pair
possibilities for each locus for each individual. Alleles were defined using the
IMGT/HLA Release: 3.22.0 2015 October 10. Best-call allele pairs for each locus in
each individual were determined based on local guidelines prioritizing alleles that
were denoted Common and Well-Documented.
Analysis of glycophorin structural variants. We tested for association and
conducted meta-analysis for glycophorin region variants in the same way as
described above for other variants. Four CNVs were imputed with reasonable
frequency and imputation quality (DUP1; the glycophorin B deletions DEL1 and
DEL2, and DUP4). We note that glycophorin region SNPs appear in our meta-
analysis results twice—once using the genome-wide combined reference panel and
once based on this imputation of glycophorin variants. In our main presentation
for consistency, we refer to the genome-wide panel imputation results, except for
glycophorin CNVs, which are imputed from the glycophorin panel.
Analysis of polygenicity of severe malaria. We aimed to assess the degree to
which additional polygenic effects explain SM susceptibility. The epidemiology of
malaria differs between sub-Saharan Africa and elsewhere, and we chose to restrict
attention to the African populations in our data for this analysis. We further
restricted attention to a subset of 13,088 samples having pairwise relatedness < 0.05
(estimated in each population based on the kinship matrix used to compute PCs
from phased genotypes, as described above). We used the genotypes at directly
typed SNPs in the phased dataset for heritability estimation.
We used two previously published methods (GCTA98 and PCGC22, in
the implementation by Gaurav Bhatia (https://github.com/gauravbhatia1/
PCGCRegression)), to estimate the heritability of SM. These methods are both
based on the infinitesimal model of genotype-trait association, under which all
variants contribute equally, in expectation, to trait variation. However, they
differ in how estimation is performed. In particular, PCGC is thought to be
more robust for case/control traits and we use it for our main results.
We estimated heritability based on the phased dataset in several ways:
in each chromosome separately
in a joint model in which all chromosome were included as separate
components
in a joint model in which the four previously confirmed association regions and
the rest of the genome were included as separate components
in a joint model in which regions near protein-coding genes and the rest of the
genome were included as separate components
in a joint model in which variants in different minor allele frequency bins were
allocated to different components.
For our main analysis, we included an indicator of country and 20 PCs,
computed across the 13,088 samples, as covariates. GCTA takes covariates into
account directly; to adjust for covariates in PCGC, we used the --adjust-grm option
in LDAK25 to subtract covariates from the relatedness matrix (however, we did not
further explore using the LDAK model for heritability estimation). For some
analyses, we also included the protective dosages of risk alleles at HbS, rs8176719
(ABO), rs4951377 (ATP2B4) and DUP4 as covariates. We also explored including
10 or 50 PCs as covariates, with little difference in results. We observed slightly
smaller estimates of heritability using GCTA than PCGC, consistent with the
previously reported theory and observations22. Although our populations are
highly structured, estimated of per-chromosome heritability when fitting
chromosomes independently or jointly were similar (Supplementary Fig. 4). This
suggests that any between-chromosome correlations between variants, which can
occur as a result of population structure, are being adequately controlled for by our
inclusion of covariates.
Between-continent allele frequency differentiation. For a malaria-associated
variant, the malaria hypothesis suggests that natural selection will maintain the
protective allele at higher frequency in populations of high childhood mortality
(such as African populations in our study) due to malaria. To assess this while
avoiding confounding by selection of variants through our GWAS (conducted in a
sample that is largely from sub-Saharan Africa), we aimed to condition on the
African allele frequency and ask whether the allele is at lower frequency in non-
endemic populations. We first computed the empirical allele count distribution
between the African continental group (AFR) and non-African continental groups
G (where G= EUR or EAS) in the reference panel, based on all variants which had
an ancestral allele assignment and which were not masked by the 1000 Genomes
strict mask. Let D= (dij) be the matrix of derived allele counts, where i ranges from
0 to the number of haplotypes in G and j ranges from 0 to the number of hap-
lotypes in AFR. For any given derived allele x, we computed upper and lower ranks
of the allele in G, conditional on its count in AFR, as
rankþG xð Þ ¼
X
i>a
dib þ 1=2dab
 !
=
X
i
dib
 !
ð13Þ
and
rankG xð Þ ¼
X
i<a
dib þ 1=2dab
 !
=
X
i
dib
 !
ð14Þ
where a is the number of x alleles in G and b is the number of x alleles in AFR.
These quantities can thus be interpreted as the upper and lower rank of the
allele x among all derived alleles with the same allele count in AFR, and satisfy
rank+G(x)+ rank−G(x)= 1. To compute the African allele counts in D, we used
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only samples from non-admixed African populations (i.e., excluding ACB and
ASW populations).
For any variant v associated with malaria, let x be the derived allele of v. We
defined rankG(v) as rank−G(x) if x is associated with decreased risk, or rank+G(x) if
x is associated with increased risk. Where unclear, we determine the direction of
effect of x based on the effect size estimated for CM. Fig. 7a depicts rankEUR(v) for
the 91 autosomal variants with BFavg > 1000, which have an ancestral allele
assignment in the 1000 Genomes ancestral allele sequence. We also annotated
variants genome-wide with rankEUR and rankEAS.
Within-Africa allele frequency differentiation. To assess differentiation within
Africa, we implemented a model similar to Bayenv99 but with simplifications that
we now describe. The Bayenv model assumes that the vector of underlying allele
frequencies in sampled populations (denoted F) follows a multivariate normal
distribution of the form
F  MVNðf0; f0ð1 f0ÞΩÞ ð15Þ
Here, f0 denotes the conceptual ancestral allele frequency (assumed to reflect a time
point T before the populations from which study samples were drawn separated)
and the matrix Ω captures the effects on allele frequency of the co-ancestry of
populations since T. In particular, diagonal entries of Ω reflect levels of genetic drift
(relative to the population at time point T) and off-diagonal entries reflect shared
ancestry between populations.
The model above is expected to hold approximately provided f0 is not too small
and the levels of genetic drift are not too large99. As the co-ancestry matrix Ω is
assumed to be the same across all neutrally evolving variants, it can be estimated
from a set of neutral SNPs across the genome. Specifically, for each variant, a vector
of scaled frequencies can be computed as
F0 ¼ ðF f0Þ=pðf0ð1 f0ÞÞ ð16Þ
Under the model above, Ω can now be estimated as the covariance of scaled
allele frequencies, Ω= cov(F′).
To implement this in practice, we made the following simplifying assumptions.
First, we restricted attention to the 7 African study populations with >200 control
samples (namely Gambia, Burkina Faso, Ghana, Cameroon, Malawi, Tanzania and
Kenya) and assumed that the population allele frequency vector F is accurately
estimated by the observed allele frequencies (using only control samples). Second,
we assumed that the ancestral allele frequency f0 is well estimated as the mean of
the per-population frequency estimates. Third, we restricted attention to directly
typed SNPs with mean allele frequency in the range 2–98% and we assumed that
the effects of allele frequencies reaching frequency 0 or 1, which is not explicitly
modelled in the above framework, would be minor. We sampled a subset of
100,000 such SNPs randomly across the genome with the above properties and
computed Ω as the empirical covariance in scaled estimated allele frequencies. The
estimated matrix Ω' is visualized in Supplementary Fig. 9. We note that the Bayenv
method avoids these assumptions by integrating over the uncertainty in ancestral
and current allele frequencies99, and by modelling the population frequencies as
bounded between 0 and 1, but requires a computationally expensive Markov Chain
Monte-Carlo (MCMC) process.
In practice, systematic effects in F' may arise due to the selection of variants
used in estimation. In addition to Ω', we therefore additionally estimated the mean
scaled frequency, denoted μ.
The estimated covariance matrix Ω' provides a model for allele frequency
variation of putatively neutral alleles in the populations considered. We visualized
this model by plotting the joint distribution of observed and simulated allele
frequencies. Specifically, we simulated 1,000,000 variants by sampling f0 from the
observed list of mean allele frequencies and then sampling allele frequencies from
Eq. (15). We then plotted the joint allele frequency distribution in the two most
divergent populations, Gambia and Kenya (Supplementary Fig. 9).
For each typed or imputed variant, we tested for differentiation against this model
as follows. We first computed the mean allele frequency and scaled allele frequency
vector F' for the variant. The model above states that F′ ~MVN(μ,Ω'), or equivalently
X  MVNð0; IdÞ ð17Þ
where X= L−1 (F′− μ) and LLt =Ω′ denotes the Cholesky decomposition of the
estimated matrix Ω'. In practice, the use of mean allele frequency implies that Ω' has
rank one less than the number of populations99 and we therefore remove one
population from the vector F' and from Ω' before computing this decomposition. In
the results presented here, we chose to remove Cameroon, which is the most central
population both geographically and within Ω (Supplementary Fig. 9). Under the
model, the sum of squared entries of X, i.e., XtX, is now distributed as χ2-distribution
with 6 degrees of freedom. We denote the corresponding P-value as PXtX.
Supplementary Fig. 10 compares the distribution of the XtX test statistic against
the χ2-distribution for typed and imputed variants at different frequencies.
Supplementary Fig. 11 depicts -log10 PXtX for all imputed variants with mean allele
frequency in the range 2–98%.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Illumina Omni 2.5 M genotype data from study samples (Fig. 1a, right panel),
corresponding phased and imputed datasets, genotypes generated on the Sequenom
iPLEX Mass-Array platform for selected variants in discovery and replication samples,
and HLA allele genotypes for 31 Gambian individuals (Supplementary Data 5) have been
deposited in the European Genome-Phenome Archive (EGA; study accession
EGAS00001001311). Whole-genome sequence read data for samples from Burkina Faso,
Cameroon and Tanzania (Fig. 1a, left panel) have been deposited in the EGA (study
accession EGAS00001003648). Access to MalariaGEN datasets on EGA is by application
to an independent data access committee. Sequence read data for Gambian Genome
Variation Project samples (Fig. 1a, left panel) is available under open access terms
through the European Nucleotide Archive (PRJEB3013 (Fula), PRJEB3252 (Jola),
PRJEB1682 (Mandinka) and PRJEB1323 (Wollof)) and the 1000 Genomes Project data
portal (https://www.internationalgenome.org). A full set of association summary
statistics underlying our analysis are available for download through the MalariaGEN
website (https://www.malariagen.net/resource/25) and the NHGRI-EBI GWAS Catalog
(https://www.ebi.ac.uk/gwas/downloads/summary-statistics). The source data underlying
Figs. 2a, 3, 4, 7 and Supplementary Figs. 5–7 are provided as a Source Data file. Further
details of data and additional resources underlying this manuscript can be found on the
MalariaGEN website (https://www.malariagen.net/resource/25).
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Software underlying the analyses in this paper and further resources are available at
http://www.malariagen.net/resource/25.
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